Literature DB >> 1864604

Dominant mutations in familial lethal and severe osteogenesis imperfecta.

L Cohen-Solal1, J Bonaventure, P Maroteaux.   

Abstract

Four families presenting with familial osteogenesis imperfecta (OI) have been studied: 2 with the lethal type II and 2 with the severe type III form. Fibroblasts of the patients, all issue from non-consanguineous parents, produced normal and abnormal alpha(I) chains. These heterozygous mutations differentiate the recurrent forms from homozygous mutations characteristic of autosomal recessive forms. Although the identity of the mutations could not be determined, such recurrence of autosomal dominant OI is probably the result of germinal mosaicism in one of the parents. Biochemical results were consistent with a somatic mosaicism in the father's fibroblasts in one family. Moreover, our studies show that not only OI type II but also severe OI type III can arise from gonadal mosaicism. We discuss the importance of such a phenomenon for genetic counseling.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864604     DOI: 10.1007/bf00200907

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  29 in total

1.  [Microdetermination of hydroxyproline with chloramine-T and p-dimethylaminobenzaldehyde].

Authors:  H STEGEMANN
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1958

2.  Human genetics. Bone disease cracks genetics.

Authors:  B Sykes
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

3.  A single base mutation that converts glycine 907 of the alpha 2(I) chain of type I procollagen to aspartate in a lethal variant of osteogenesis imperfecta. The single amino acid substitution near the carboxyl terminus destabilizes the whole triple helix.

Authors:  C T Baldwin; C D Constantinou; K W Dumars; D J Prockop
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

4.  Substitution of arginine for glycine 664 in the collagen alpha 1(I) chain in lethal perinatal osteogenesis imperfecta. Demonstration of the peptide defect by in vitro expression of the mutant cDNA.

Authors:  J F Bateman; S R Lamande; H H Dahl; D Chan; W G Cole
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

5.  Molecular weight determination of membrane protein and glycoprotein subunits by discontinuous gel electrophoresis in dodecyl sulfate.

Authors:  D M Neville; H Glossmann
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

6.  Osteogenesis imperfecta type III. Delineation of the phenotype with reference to genetic heterogeneity.

Authors:  D O Sillence; K K Barlow; W G Cole; S Dietrich; A P Garber; D L Rimoin
Journal:  Am J Med Genet       Date:  1986-03

7.  Collagen defects in lethal perinatal osteogenesis imperfecta.

Authors:  J F Bateman; D Chan; T Mascara; J G Rogers; W G Cole
Journal:  Biochem J       Date:  1986-12-15       Impact factor: 3.857

8.  A lethal variant of osteogenesis imperfecta has a single base mutation that substitutes cysteine for glycine 904 of the alpha 1(I) chain of type I procollagen. The asymptomatic mother has an unidentified mutation producing an overmodified and unstable type I procollagen.

Authors:  C D Constantinou; K B Nielsen; D J Prockop
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

9.  Characterization of point mutations in the collagen COL1A1 and COL1A2 genes causing lethal perinatal osteogenesis imperfecta.

Authors:  S R Lamande; H H Dahl; W G Cole; J F Bateman
Journal:  J Biol Chem       Date:  1989-09-25       Impact factor: 5.157

10.  Osteogenesis imperfecta. The position of substitution for glycine by cysteine in the triple helical domain of the pro alpha 1(I) chains of type I collagen determines the clinical phenotype.

Authors:  B J Starman; D Eyre; H Charbonneau; M Harrylock; M A Weis; L Weiss; J M Graham; P H Byers
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

View more
  7 in total

1.  A dominant mutation in the COL1A1 gene that substitutes glycine for valine causes recurrent lethal osteogenesis imperfecta.

Authors:  J Bonaventure; L Cohen-Solal; C Lasselin; P Maroteaux
Journal:  Hum Genet       Date:  1992-08       Impact factor: 4.132

2.  Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible.

Authors:  G A Wallis; B Sykes; P H Byers; C G Mathew; D Viljoen; P Beighton
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

3.  Gonadal mosaicism and familial adenomatous polyposis.

Authors:  Angela L Schwab; Thérèse M F Tuohy; Michelle Condie; Deborah W Neklason; Randall W Burt
Journal:  Fam Cancer       Date:  2007-11-18       Impact factor: 2.375

4.  Genetic counselling on brittle grounds: recurring osteogenesis imperfecta due to parental mosaicism for a dominant mutation.

Authors:  M Raghunath; K Mackay; R Dalgleish; B Steinmann
Journal:  Eur J Pediatr       Date:  1995-02       Impact factor: 3.183

5.  CRTAP mutations in lethal and severe osteogenesis imperfecta: the importance of combining biochemical and molecular genetic analysis.

Authors:  Fleur S Van Dijk; Isabel M Nesbitt; Peter G J Nikkels; Ann Dalton; Ernie M H F Bongers; Jiddeke M van de Kamp; Yvonne Hilhorst-Hofstee; Nicolette S Den Hollander; Augusta M A Lachmeijer; Carlo L Marcelis; Gita M B Tan-Sindhunata; Rick R van Rijn; Hanne Meijers-Heijboer; Jan M Cobben; Gerard Pals
Journal:  Eur J Hum Genet       Date:  2009-06-24       Impact factor: 4.246

6.  Osteogenesis Imperfecta: A Review with Clinical Examples.

Authors:  F S van Dijk; J M Cobben; A Kariminejad; A Maugeri; P G J Nikkels; R R van Rijn; G Pals
Journal:  Mol Syndromol       Date:  2011-10-12

7.  A novel mutation in LEPRE1 that eliminates only the KDEL ER- retrieval sequence causes non-lethal osteogenesis imperfecta.

Authors:  Masaki Takagi; Tomohiro Ishii; Aileen M Barnes; Maryann Weis; Naoko Amano; Mamoru Tanaka; Ryuji Fukuzawa; Gen Nishimura; David R Eyre; Joan C Marini; Tomonobu Hasegawa
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.